Also, it has been reported that for patients with high PD-L1 expression in tumor cells, PD-1/PD-L1 blockade is more effective than in those with a low expression of PD-L1 [25–27], which may be due to the sensitivity to immune checkpoint with anti-PD-1 treatment. The gene discussed is CD274; the disease is neoplasm.